Shots:

• Mitokinin to receive an up front and will continue to develop its PINK1 activator program through completion of IND enabling studies for its lead compound. If IND-enabling studies are successful- AbbVie will have the option to acquire Mitokinin
• The focus of the agreement is to advance Mitokinin's PINK1 activator program to treat PD
• Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1 and aims to address the mitochondrial dysfunction contributing to PD pathogenesis and progression

 ­ Ref: PRNewswire | Image: PRNewswire